The proteasome cap RPT5/Rpt5p subunit prevents aggregation of unfolded ricin A chain [PDF]
, 2013 The plant cytotoxin ricin enters mammalian cells by receptor-mediated endocytosis, undergoing retrograde transport to the endoplasmic reticulum (ER) where its catalytic A chain (RTA) is reductively separated from the holotoxin to enter the cytosol and ...
Spooner, Robert A. +12 more
core +1 more source
Pharmaceuticals, 2023 Cancer is a complex multifactorial disease whose pathophysiology involves multiple metabolic pathways, including the ubiquitin–proteasome system, for which several proteasome inhibitors have already been approved for clinical use. However, the resistance
Romina A. Guedes +12 more
doaj +1 more source
The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. [PDF]
, 2014 p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and
J Das +11 more
core +1 more source
Current Oncology, 2023 Proteasome inhibitors are moieties targeting the proteolytic activity of a proteasome, with demonstrated efficacy in certain hematological malignancies and candidate drugs in other types of cancer, including glioblastoma (GBM). They disturb the levels of
Agata Gozdz
doaj +1 more source
Inhibitory activity and antiparasite activity of kinetoplastid proteasome inhibitors.
, 2021 Inhibitory activity and antiparasite activity of kinetoplastid proteasome inhibitors.
Gang Lin (824266), Hao Zhang (15339)
core +1 more source
Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases [PDF]
, 2021 The 26S proteasome is the principal protease for regulated intracellular proteolysis. This multi-subunit complex is also pivotal for clearance of harmful proteins that are produced throughout the lifetime of eukaryotes.
Muniyappan, Srinivasan +7 more
core +1 more source
Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer
Molecular & Cellular Oncology, 2017 The proteasome machinery is a common target of gain-of-function p53 missense mutants. Upregulation of the proteasome fosters chemoresistance to proteasome inhibitors.
Kamil Lisek +2 more
doaj +1 more source
Different degree in proteasome malfunction has various effects on root growth possibly through preventing cell division and promoting autophagic vacuolization. [PDF]
PLoS ONE, 2012 The ubiquitin/proteasome pathway plays a vital role in plant development. But the effects of proteasome malfunction on root growth, and the mechanism underlying this involvement remains unclear.
Xianyong Sheng +5 more
doaj +1 more source
Rational design of novel phenol ether derivatives as non-covalent proteasome inhibitors through 3D-QSAR, molecular docking and ADMET prediction [PDF]
Exploration of Drug Science, 2023 Aim: The purpose of this paper is to use different structures and ligand-based drug design methods properly to provide theoretical guidance for the design of novel non-covalent proteasome inhibitors, and conduct theoretical analysis of the binding ...
Miao Yuan +4 more
doaj +1 more source
Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats.
PLoS ONE, 2019 Chemical proteasome inhibition has been a valuable animal model of neurodegeneration to uncover roles for the ubiquitin-proteasome system in the central nervous system.
Masaaki Kageyama +4 more
doaj +1 more source